Supply is limited for one rabies immune globulin product. Imogam (produced by Sanofi Pasteur) is only available to healthcare providers who have a patient with current suspected rabies exposure requiring immediate post-exposure prophylaxis (PEP).
  • Health care providers should continue to administer rabies post-exposure prophylaxis when indicated.
  • There are rabies vaccine and rabies immune globulin products available.​
  • For current information about supply and directions for requesting products, please visit the Centers for Disease Control and Prevention's (CDC) webpage: Rabies: Vaccine and Immune Globulin Availability.
    • The webpage has detailed information about which products are currently available and how to obtain products.
    • The CDC site will be updated as new information is available, so check back, as needed.


Rabies is a viral disease affecting the central nervous system. The rabies virus is transmitted from infected mammals to humans (typically via a bite) and is invariably fatal once symptoms appear. Human rabies is now rare in the United States, but still occurs frequently in many developing nations. The last four cases of human rabies in Wisconsin occurred in 1959, 2000, 2004 and 2010. All four Wisconsin cases acquired the disease from infected bats.

Animal Bites | Diagnostic testing | Rabies in Wisconsin

Information on this page has been organized into three categories. Please choose one of the following tabs.

Additional Info Group

Last Revised: January 3, 2020